{"id":"W4306739715","doi":"10.1016/j.breast.2022.10.007","title":"Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer","year":2022,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"EMD Serono; Genentech; PharmaMar; G1 Therapeutics; MacroGenics; Pfizer; Incyte; NuCana; Seagen; Relay Therapeutics; Plexxikon; Ontario Brain Institute; Syndax Pharmaceuticals; Regeneron Pharmaceuticals; Amgen; Radius Health; Gilead Sciences; Merck; Mersana Therapeutics; Novartis; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Roche; Astellas Pharma US","keywords":"Medicine; Metastatic breast cancer; Antibody-drug conjugate; Drug; Cancer; Antibody; Breast cancer; Oncology; Conjugate; Drug development; Cancer research; Internal medicine; Pharmacology; Immunology; Monoclonal antibody","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009287458,0.0004058435,0.0004160879,0.0003815161,0.0001363827,0.0005634024,0.0003281041,0.0006336247,0.002194352],"category_scores_gemma":[0.0005622419,0.0001932095,0.0002382403,0.0003946202,0.000251719,0.0004250088,0.0003144311,0.0009133875,0.0008060725],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004312106,"about_ca_system_score_gemma":0.0005488531,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007293239,"about_ca_topic_score_gemma":0.001213347,"domain_scores_codex":[0.9998466,0.00004304499,0.00000736942,0.00002226669,0.00004568315,0.0000350767],"domain_scores_gemma":[0.99983,0.00002650801,0.00002646813,0.000007805384,0.00004034641,0.00006876942],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.003009332,0.002628924,0.002230231,0.001004117,0.0000924335,0.0008567265,0.0003710381,0.002715136,0.2729343,0.003298296,0.01074722,0.7001123],"study_design_scores_gemma":[0.01309743,0.07298602,0.02307058,0.0005681001,0.0002997577,0.00986474,0.0001821946,0.00895739,0.2966378,0.002019023,0.5722046,0.0001122857],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6910909,0.2381109,0.02640375,0.004230167,0.0007784212,0.001955086,0.001584797,0.001095671,0.03475032],"genre_scores_gemma":[0.8755597,0.09617613,0.014128,0.001604831,0.0002627166,0.0006390918,0.002155811,0.00008758259,0.00938612],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002194352,"threshold_uncertainty_score":0.007340789,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05927251587468007,"score_gpt":0.4248498023256788,"score_spread":0.3655772864509987,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}